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ABSTRACT
Objective: Peroxisomal blood tests are generally considered to be conclusive. We observed
several patients with a clinical and MRI phenotype suggestive of an infantile onset peroxi-
somal defect, but no convincing abnormalities in initial peroxisomal blood tests. Brain MRI
showed typical abnormalities as observed in the neonatal adrenoleukodystrophy variant of
infantile peroxisomal disorders. Our aim was to evaluate the accuracy of this MRI diagnosis
with further peroxisomal testing.
Methods: We searched our database of unclassified leukoencephalopathies and found 6 such
patients. We collected clinical data and scored available MRIs of these patients. We performed
further peroxisomal studies in fibroblasts, including immunofluorescence microscopy analysis
with antibodies against catalase, a peroxisomal matrix enzyme. We performed complementation
analysis and analyzed the suspected genes.
Results: We confirmed the diagnosis of Zellweger spectrum disorder in 3 patients and
D-bifunctional protein deficiency in the others. The clinical findings were within the spectrum
known for these diagnoses. Sequential MRIs showed that the abnormalities started in the hilus of
the dentate nucleus and superior cerebellar peduncles. Subsequently, the cerebellar white matter
and brainstem tracts were affected, followed by the parieto-occipital white matter, splenium of
the corpus callosum, and posterior limb of the internal capsule. Eventually, all cerebral white
matter became abnormal. The thalamus was typically affected as well.
Conclusions: If MRI reveals abnormalities suggestive of infantile onset peroxisomal defects, neg-
ative peroxisomal blood tests do not exclude the diagnosis. Further tests in fibroblasts should be
performed, most importantly immunofluorescence microscopy analysis with antibodies against
catalase to stain peroxisomes. Neurology® 2012;78:1304–1308
GLOSSARY
DBP  D-bifunctional protein; DHAPAT  dihydroxyacetonephosphate-acyltransferase; DHCA  dihydroxycholestanoic
acid; IRD infantile Refsum disease; NALD neonatal adrenoleukodystrophy; THCA trihydroxycholestanoic acid; VLCFA
very long-chain fatty acid; ZS Zellweger syndrome; ZSD Zellweger spectrum disorder.
Clinically, Zellweger spectrum disorders (ZSDs) and the single peroxisomal -oxidation de-
fects acyl-CoA oxidase 1 (ACOX1) and D-bifunctional protein (DBP) deficiency resemble
each other.1–5 They cannot always be distinguished without laboratory tests. The clinical syn-
dromes comprising the ZSDs, i.e., Zellweger syndrome (ZS), neonatal adrenoleukodystrophy
(NALD), and infantile Refsum disease (IRD), were described before their biochemical and
molecular bases were understood.4,5
This article is focused on the milder NALD-like variant of ZSDs, and ACOX1 and DBP
deficiency. Most patients with these disorders present at or soon after birth, but reach some
milestones before neurologic deterioration starts between 1 and more than 7 years.1–5 MRI in
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these disorders shows perisylvian polymicro-
gyria or no gyral abnormalities.6 The earliest
changes related to demyelination are seen in
the cerebellum and subsequently involve
brainstem, posterior limb of the internal cap-
sule, and posterior cerebral white matter.6
Biochemical abnormalities in ZSDs in-
clude increased plasma levels of very long-
chain fatty acids (VLCFAs), phytanic and
pristanic acid, bile acid intermediates di-
and trihydroxycholestanoic acid (DHCA and
THCA), and decreased erythrocytes levels of
plasmalogens.4,5 The abnormalities in DBP
deficiency are the same except for normal
plasmalogen levels.1 ACOX1 deficiency is
characterized by the exclusive accumulation
of VLCFAs.2 Peroxisomal parameters can also
be studied in fibroblasts, including investiga-
tion of number and size of peroxisomes by
immunofluorescence microscopy.1
We observed patients with the clinical and
MRI phenotype of an infantile onset peroxi-
somal disorder, but without convincing ab-
normalities of peroxisomal parameters in
plasma. We decided to evaluate the accuracy
of the MRI diagnosis with further peroxi-
somal testing.
METHODS This retrospective study received approval of the
institutional review board with waiver of informed consent. We
searched our database of approximately 3,000 patients with a
leukoencephalopathy of unknown origin with the following in-
clusion criteria: 1) MRI features typical of the NALD variant of
ZSDs, ACOX1 or DBP deficiency, as outlined in the introduction;
and 2) normal or only mildly abnormal peroxisomal parameters in
blood (nonfasting samples) as determined by different laboratories,
including plasma VLCFAs, phytanic and pristanic acid, bile acids,
and plasmalogens in erythrocytes. We collected clinical data and
evaluated available MRIs of these patients.
Studies in cultured fibroblasts, performed at the Laboratory
Genetic Metabolic Diseases, Amsterdam, included 1) determina-
tion of VLCFA profile; 2) measurement of enzymatic activity of
dihydroxyacetonephosphate-acyltransferase (DHAPAT); 3) im-
munofluorescence microscopy analysis using antibodies against
catalase, a peroxisomal matrix enzyme; and 4) measurement of
peroxisomal - and -oxidation. When these studies revealed a
ZSD, complementation testing was performed in fibroblasts
to identify the associated gene,7 followed by molecular analy-
sis of this gene. When these studies revealed a single enzyme
deficiency, activity of the peroxisomal -oxidation enzymes
DBP1 or ACOX12 was determined, followed by molecular
analysis of HSD17B4 for DBP deficiency and ACOX1 for
ACOX1 deficiency.
RESULTS Clinical features. Six patients fulfilled the
above MRI and laboratory criteria. Clinical details
are summarized in table e-1 on the Neurology® Web
site at www.neurology.org. Patient 1 has been de-
scribed before.8 Patients 2 and 6 are brothers. Four
patients presented after birth with seizures. Early de-
velopment was severely delayed in 3 patients: mildly
delayed in 1, who achieved walking with support;
and normal in 2, who achieved unsupported walk-
ing. Onset of deterioration in our patients was
around 2 years. Patients became spastic and ataxic
and lost all developmental milestones. Sensorineural
Figure 1 D-bifunctional protein deficiency
Axial T2-weighted images of patient 2 at 2 years, 4 months (A, B) and 4 years, 3 months (C,
D), and his brother at 1 month (E). The first MRI shows mild signal abnormalities in the hilus
of the dentate nucleus (black arrow in A) and superior cerebellar peduncles (white arrow-
head in A). There are no evident supratentorial signal abnormalities (B). Follow-up MRI
shows signal abnormalities in the hilus of the dentate nucleus, cerebellar white matter, su-
perior and middle cerebellar peduncles, medial lemniscus (white arrow in C), pyramidal
tracts (black arrow in C), parieto-occipital white matter, posterior limb of the internal cap-
sule, and thalami. Early MRI in the brother shows bilateral polymicrogyria in the area of the
Sylvian fissure (E).
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deafness, decreased vision, and polyneuropathy oc-
curred in some.
Initial laboratory results. Laboratory findings are
summarized in table e-2. In 5 patients, initial testing
of peroxisomal parameters in blood revealed no or
little evidence of peroxisomal dysfunction. In partic-
ular, VLCFAs were either normal or mildly elevated
with abnormal C24:0/C22:0 and C26:0/C22:0 ra-
tios. In patient 5, mildly increased levels of VLCFAs,
phytanic acid, and pristanic acid were measured,
but initial biochemical studies in fibroblasts were
normal.
MRI abnormalities. MRI findings are summarized in
table e-3. Patients 2 and 6 underwent neonatal MRI.
In patient 2, this MRI was not available but reported
as normal. Patient 6 was the only one with perisyl-
vian polymicrogyria (figure 1E). Five patients under-
went MRI after the onset of neurologic deterioration
between ages 2 and 31⁄2 years. Delayed myelination
and signal abnormalities in the hilus of the dentate
nucleus and the superior cerebellar peduncles were
seen in all (figures 1 and 2). Four patients had more
extensive brainstem, cerebellar, and cerebral white
matter abnormalities, especially the parieto-occipital
white matter and posterior part of the corpus callosum.
Four patients had follow-up MRIs 1–2 years later
(figures 1 and 2). These showed diffuse abnormalities
of the brainstem, cerebellar and cerebral white mat-
ter. The thalamus became affected in all patients.
Two patients received contrast; no enhancement was
found.
These MRI findings indicated that the patients
most likely had a peroxisomal disorder and instigated
further studies.
Peroxisomal testing in fibroblasts. Although also in
fibroblasts some parameters, like VLCFAs, were nor-
mal or only mildly abnormal, immunofluorescence
microscopy analysis showed aberrant peroxisomal
staining in all cell lines (table e-2).
In cells from patients 3, 4, and 5, a mosaic pattern
was seen with cells with peroxisomal staining, cells
with a reduced number of peroxisomes, and cells
without peroxisomal staining (figure 3B). When cul-
tured at 40°C, cells lost all peroxisomal staining (fig-
Figure 2 Zellweger spectrum disorder
Axial T2-weighted images of patient 3 at 3 years, 4 months (A–C) and 5 years, 4 months (D–F). The first MRI shows signal
abnormalities in the hilus of the dentate nucleus, superior cerebellar peduncles, medial lemniscus (white arrows in A and B),
and pyramidal tracts (black arrow in A). There are beginning signal abnormalities in the occipital white matter (C). Follow-up
MRI shows signal abnormalities in the hilus of the dentate nucleus and cerebellar white matter (D), pyramidal tracts (black
arrow in E), temporal (E), parieto-occipital (F), and frontal (F) white matter, splenium of the corpus callosum (F), posterior limb
of the internal capsule (F), and thalami (F).
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ure 3C), indicative of ZSD.9 Complementation
testing revealed defects of PEX13 for patients 3 and
4, and PEX6 for patient 5. Molecular studies in pa-
tient 4 revealed a homozygous mutation in PEX13
and in patient 5 a homozygous mutation in PEX6
(table e-2). In patient 3, no mutations were identi-
fied in the coding region of PEX13.
Immunofluorescence microscopy of cells from pa-
tients 1 and 6 revealed a reduced number of enlarged
peroxisomes, indicative of a single peroxisomal
-oxidation defect (figure 3D). Enzyme analysis re-
vealed deficient activity of the dehydrogenase compo-
nent of DBP in patient 1, and deficient activity of both
the hydratase and dehydrogenase components of DBP
in patients 2 and 6. In all 3 patients mutations were
found in HSD17B4 (table e-2).
DISCUSSION The clinical picture of the present
patients was suggestive of the NALD variant of ZSDs
or single peroxisomal -oxidation defects. Limited
peroxisomal testing performed in different laborato-
ries revealed no convincing abnormalities. In all pa-
tients MRI showed typical abnormalities associated
with ZSDs or single peroxisomal -oxidation de-
fects, which prompted further testing in fibroblasts.
A peroxisomal defect was confirmed in all. A similar
case has been published recently.10 These observa-
tions show that if MRI indicates a ZSD or single
peroxisomal -oxidation defect, negative initial per-
oxisomal tests do not rule out such disease, and
that further peroxisomal studies in fibroblasts and
molecular analyses to identify the gene defect are
warranted.
Additionally, our study provides information on
the sequence of demyelination in the NALD variant
of ZSD and single peroxisomal -oxidation defects.
It starts in the hilus of the dentate nucleus and supe-
rior cerebellar peduncles, the outflow tracts of the
dentate nucleus. Subsequently, the cerebellar white
matter and brainstem are affected, especially the py-
ramidal tracts, medial lemniscus, and superior, mid-
dle, and inferior cerebellar peduncles. Next, the
parieto-occipital white matter with relative sparing of
the U-fibers, the splenium of the corpus callosum,
and the posterior limb of the internal capsule are af-
fected. The demyelination is progressive and finally
involves all cerebral hemispheric white matter. The
thalamus is typically affected as well. No contrast en-
hancement occurs.
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